Actively Recruiting
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
Led by Miguel Pampaloni · Updated on 2026-05-01
50
Participants Needed
1
Research Sites
525 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this project is to determine the role of FDOPA/PET as a pre-operative diagnostic imaging procedure for differentiating focal and diffuse forms of congenital hyperinsulinism and locating focal lesions in the pancreas to guide surgical resection.
CONDITIONS
Official Title
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Any age, primarily infants 0-6 months due to typical age of initial presentation
- Diagnosis of focal or diffuse congenital hyperinsulinism based on clinical criteria and confirmed by genetic testing for mutations in ABCC8 and KCNJ1
- Hypoglycemia not controlled with medical treatment such as diazoxide or octreotide
- Able to stop medications in time to wash out before the PET scan
- Patients with uncontrolled hypoglycemia after partial or near-total pancreatectomy
- Normal liver and kidney function
You will not qualify if you...
- Treatment with third-line medications for hyperinsulinism like nifedipine or glucagon
- Liver or kidney insufficiency
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here